4Rinta-Kokkoa H,Dagan R,Givon-lavi N,et al.Estimation of vaccineefficacy against acquisition of pneumococcal carriage.Vaccine,2009,27(29):3831-3837.
5Kohberger RC,Jemiolob D,Noriegab F.Prediction of pertussisvaccine efficacy using a correlates of protection model.Vaccine,2008,26(27-28):3516-3521.
6Hirotay Y,Kajit M,Ide S,et al.Antibody efficacy as a keen indexto evaluate influenza vaccine effectiveness.Vaccine,1997,15(9):962-967.
7Ward RL,Bemstein DI.Lack of correlation between serum rotavirusantibody titers and protection following vaccination with reassortantRRV vaccines.Vaccine,1995,13(13):1226-1232.
8Lindh E.Increased resistance of immunoglobulin A dimers toproteolytic degradation after binding of secretory component.Immunology,1975,114(Pt 2):284-286.
9Berdoz J,Blanc CT,Reinhardt M,et al.In vitro comparison of theantigen-binding and stability properties of the various molecularforms of IgA antibodies assembled and produced in CHO cells.ProcNatl Acad Sci USA,1999,96:3029-3034.
10Quan CP,Berneman A,Pires R,et al.Natural polyreactive secretoryimmunoglobulin A autoantibodies as a possible barrier to infectionin humans.Infect Immun,1997,65:3997-4004.
